menu
    • menu
    [{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"||Phosphodiesterase 4","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Global Coalition for Adaptive Research \/ Undisclosed"},{"orgOrder":0,"company":"National Center for Global Health and Medicine","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Eritoran","moa":"Toll-like receptor 4\/MD-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Center for Global Health and Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Center for Global Health and Medicine \/ Eisai","highestDevelopmentStatusID":"4","companyTruncated":"National Center for Global Health and Medicine \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Coalition For Adaptive Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Eritoran","moa":"Toll-like receptor 4\/MD-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ The Global Coalition For Adaptive Research","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ The Global Coalition For Adaptive Research"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eritoran","moa":"Toll-like receptor 4\/MD-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Eritoran

    Menu

    Eritoran

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Global Coalition for Adaptive Research

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Global Coalition for Adaptive Research

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apremilast,Eritoran,Hydrocortisone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVI...

                            Details : Amgen & Eisai to participate in the immune modulation domain of REMAP-COVID, an adaptive clinical trial to test interventions for patients hospitalized with COVID-19. Amgen’s Apremilast & Eisai’s Eritoran to be evaluated across multiple international...

                            Product Name : Otezla

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            October 27, 2020

                            Lead Product(s) : Apremilast,Eritoran,Hydrocortisone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Center for Global Health and Medicine

                            Country arrow
                            AAPS
                            Not Confirmed

                            National Center for Global Health and Medicine

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eritoran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eisai Joins Industry-Academia-Government for the Development of Drug Discovery for Covid-19 Utilizing Eritoran...

                            Details : In this collaborative research, a non-clinical animal model of SARS-CoV-2 infection will be constructed. Additionally, TLR4 antagonist eritoran, discovered by Eisai, and an anti-FKN antibody E6011, KAN Research Institute, will be evaluated.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 06, 2020

                            Lead Product(s) : Eritoran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eisai

                            Japan arrow
                            AAPS
                            Not Confirmed

                            Eisai

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eritoran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : The Global Coalition For Adaptive Research

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Eisai to Investigate Eritoran in REMAP-COVID Study

                            Details : The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 01, 2020

                            Lead Product(s) : Eritoran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : The Global Coalition For Adaptive Research

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eisai

                            Japan arrow
                            AAPS
                            Not Confirmed

                            Eisai

                            Japan arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eritoran

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eisai Revives Eritorian as a Possible COVID-19 Treatment, Plans to Launch an International Collaborative Clini...

                            Details : Eisai has resuscitated its once-jettisoned sepsis drug eritoran, otherwise known as E5564, for the treatment of COVID-19, planning to launch a global clinical trial as early as June.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 29, 2020

                            Lead Product(s) : Eritoran

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth